The influence of race and language on chronic hepatitis C virus infection management

Céline Giordano1, Curtis Cooper

  • 1University of Ottawa, The Ottawa Hospital, Division of Infectious Diseases, Ottawa, Canada. ccooper@ottawahospital.on.ca

Insights

Race, ethnicity, and language impact healthcare for chronic hepatitis C virus (HCV) infection. Improving communication through translated materials and trained translators ensures equitable HCV treatment for all patients.

Area of Science:

  • Hepatology
  • Health Services Research
  • Health Equity

Background:

  • Chronic hepatitis C virus (HCV) infection disproportionately affects various racial and ethnic groups.
  • Standard of care for HCV treatment has advanced significantly, but access and outcomes remain uneven.
  • Patient-provider communication is a critical determinant of treatment satisfaction and adherence.

Purpose of the Study:

  • To review the epidemiology of HCV and current treatment standards.
  • To evaluate how race, ethnicity, and language influence HCV screening, diagnosis, and treatment initiation.
  • To highlight strategies for improving communication and ensuring equitable HCV care.

Main Methods:

  • Systematic literature review of studies on HCV epidemiology and treatment.
  • Analysis of factors influencing healthcare access and delivery for diverse patient populations.
  • Evaluation of communication barriers and facilitators in HCV care.

Main Results:

  • Racial, ethnic, and linguistic factors demonstrably affect HCV screening, work-up, and treatment initiation.
  • Disparities exist in the quality of care and patient satisfaction within HCV management.
  • Effective communication strategies are essential for mitigating these disparities.

Conclusions:

  • Race, ethnicity, and language are significant determinants of healthcare delivery and treatment satisfaction in chronic hepatitis C.
  • Implementing improved communication methods, such as translated documents and professional translators, is crucial.
  • Equitable delivery of high-quality HCV care necessitates addressing these socio-cultural factors.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...